• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Energy

Morning Movers: MYL, XOM, MSFT, GIS, CLVS

Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
By ANDERS KEITZ Sep 21, 2016 | 08:20 AM EDT
Stocks quotes in this article: MYL, XOM, MSFT, GIS, CLVS

The question on every investor and trader's mind will be answered today: Will the Federal Reserve raise interest rates? U.S. futures were rising ahead of today's decision, which will come at 2 p.m. EDT, followed by a press conference from Fed Chair Janet Yellen at 2:30 p.m. Many think it unlikely that the Fed will raise rates now. But perhaps the Fed is capable of a surprise.

Meanwhile, the sticker-shock over Mylan's (MYL) EpiPen goes to Washington. Shares of the drug maker were lower before CEO Heather Bresch goes in front of the House Oversight and Government Reform Committee. Bresch is expected to defend the cost for the life-saving EpiPen. In prepared testimony released by the committee ahead of her appearance, Bresch says: "Price and access exist in a balance, and we believe we have struck that balance." Still, she adds that she wishes the company had "better anticipated the magnitude and acceleration" of the rising prices for some families. The price of the EpiPen soared to $600 for a two-pack in August, which represents an increase of more than 500% since 2007.

Exxon Mobil (XOM) is being investigated by the U.S. Securities and Exchange Commission, and despite this news shares are up in early trading. The SEC is looking into how Exxon values its assets in a world of increasing climate change regulations, according to a report by the Wall Street Journal. The probe will focus on how the company calculates the impact to its business due to climate change, including what figures Exxon uses to account for the future costs of complying with regulations to curb greenhouse gases, the Journal reported. The SEC will also be investigating Exxon's longstanding practice of not writing down the value of its oil and gas reserves when prices fall, sources told the Journal.

In better news, Microsoft (MSFT) is making its investors happy this morning. The tech giant said it would raise its dividend 8% to $0.39 per share. The board also approved a share buyback program of up to $40 billion. The company said the buyback program has no expiration date and may be terminated at any time. Microsoft said it is on track to complete its existing $40 billion share repurchase program by year-end.

Cheerios maker General Mills (GIS)  shares were rising before the bell after posting better-than-expected earnings for the 2017 fiscal first quarter. The food manufacturer reported earnings of $0.78 per share, which topped Wall Street' s estimates by $0.03. Revenue of $3.91 billion fell 7% year-over-year, but was in-line with analysts' predictions. General Mills also reiterated its 2017 targets for earnings growth in the range of 6% to 8% year-over-year.

Finally, Clovis Oncology (CLVS) shares were up 10% before the opening bell after analysts with Credit Suisse boosted the stock's rating to Outperform from Neutral in a Wednesday report. Credit Suisse also hiked the firm's price target to $41 from $19, citing the potential for the Boulder, Colo.-based drug maker to receive a takeover offer given the potential market demand for its anti-cancer treatment Rucaparib.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Energy | Consumer Staples | Futures | Earnings | Economy | Oil Equipment/Services

More from Energy

No Longer an 'Aristocrat,' This Dividend Stock Still Looks Pumped

Bob Ciura
Feb 25, 2021 2:30 PM EST

Suncor Energy has a bruised but energizing 3.0% yield.

As Plug Power Plummets, There Appears to Be More Risk Ahead

Bruce Kamich
Feb 25, 2021 2:03 PM EST

Let's check out the PLUG charts as traders react to the latest EPS numbers.

This Refinery's 5.8% Dividend Yield Is Betting on a Recovery

Bob Ciura
Feb 19, 2021 12:30 PM EST

Valero Energy's dividend has not been cut, despite hard times. There is the possibility for outsized returns from a quicker than anticipated bounce back in demand, but clear risk remains.

Looking for an Energy Boost? Try Royal Dutch Shell's 3.5% Dividend Yield

Bob Ciura
Feb 18, 2021 12:32 PM EST

Shell suffered along with the rest of the oil and gas sector last year. But it could be a good dividend play once again.

First Solar's Charts Are Showing Some Cracks

Bruce Kamich
Feb 18, 2021 10:05 AM EST

It looks like FSLR has started a move lower.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:09 AM EST GARY BERMAN

    Monday Morning Fibocall for 3/1/2021

    Always a good idea to know where our bounce zones ...
  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login